Noo Li Jeon's Biography

• Home
• |
• Send WeChat Message to SelectBIO
• |
• Agenda
• |
• Exhibition
• |
• Conference Address
• |
• Registration
• |
• Co-Located Conferences
• |

High-Throughput Reproducible Organ-on-a-Chip Platform: A New Strategy for Drug Validation

Saturday, 21 November 2026 at 10:20

Add to Calendar ▼2026-11-21 10:20:002026-11-21 11:20:00Europe/LondonHigh-Throughput Reproducible Organ-on-a-Chip Platform: A New Strategy for Drug ValidationNanomedicine and LNPs Asia 2026 in Shenzhen, ChinaShenzhen, ChinaSELECTBIOenquiries@selectbiosciences.com

Accurate prediction of human drug responses during the preclinical stage is essential for successful drug development, yet conventional 2D cultures and animal models often fail to mimic complex human physiology. This seminar introduces an advanced Organ-on-a-Chip (OoC) platform designed to provide a robust validation stage for the drug discovery pipeline.

Our system moves beyond laboratory-scale research by establishing mass-production processes and high experimental reproducibility suitable for the biotech industry. By co-culturing patient-derived 3D tumor spheroids with cancer-associated fibroblasts (CAFs), we have precisely recapitulated the dense stroma and vascular microenvironments of solid tumors.

This platform allows for the evaluation of how small-molecule therapies and large biologics, as well as such as Antibody-Drug Conjugates (ADCs), penetrate the tumor microenvironment. We will present data on patient-specific efficacy and vascular toxicity resulting from endothelial barrier disruption. By combining highly reproducible chip design with sophisticated tumor modeling, this translational research platform significantly enhances clinical predictability and overcomes the limitations of traditional preclinical models.